Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 12Oxaliplatin 11Leucovorin 10Irinotecan 7Capecitabine 7regorafenib 4Radiotherapy 4Bevacizumab 4aflibercept 2Reverse Transcriptase Polymerase Chain Reaction 2Radiation 2Neoadjuvant Therapy 2Biopsy 2tucatinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1sulindac sulfone 1sargramostim 1pembrolizumab 1lonafarnib 1irofulven 1infigratinib 1dehydroftorafur 1balstilimab 1XELOX 1Trifluridine 1Trastuzumab 1Transplantation 1Sunitinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Rectal Neoplasms × irofulven × Clear all
NCT00003786 2014-03-07

Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer

University of Chicago

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡